Clinical trials: Hepatitis, Viral, Human
Hepatitis C, Chronic
An Efficacy, Pharmacokinetics, Safety and Tolerability Study of TMC435 as Part of a Treatment Regimen for Hepatitis C-Infected Patients
The purpose of this study is to provide confirmatory efficacy and safety data of TMC435 as part of a treatment regimen including peginterferon-alpha (PegIFNα-2a) and ribavirin (RBV) in patients with genotype 1 Hepatitis C virus…
- Trial name
- NCT01725529
- Testing
- TMC435, Peginterferon-alpha (PegIFNα-2a), Ribavirin (RBV)
- Where
- 21 sites in China, South Korea
- Volunteers
- 457 people
- Sponsor
- Janssen R&D Ireland
Hepatitis C Virus
The Durability of Response and Persistence of Resistance to AbbVie's 2 Direct-acting Antiviral Agent (2D) Therapy in Japanese Subjects
This study seeks to assess the durability of response and persistence of resistance to ombitasvir/ paritaprevir/ritonavir in Japanese participants who enrolled in a Phase 2 or 3 clinical study with these agents for the treatment…
- Trial name
- NCT02581020
- Where
- 53 sites in Japan
- Volunteers
- 344 people
- Sponsor
- AbbVie
Hepatitis C Virus Infection
Evaluate the Efficacy and Safety of Sofosbuvir/Velpatasvir Fixed-Dose Combination and Ribavirin for 12 Weeks in Participants With Chronic HCV Infection and Child-Pugh-Turcotte Class C Cirrhosis
The primary objectives of this study are to evaluate the efficacy, safety, and tolerability of the treatment with sofosbuvir velpatasvir (SOF/VEL) fixed-dose combination (FDC) with ribavirin (RBV) for 12 weeks in participants…
- Trial name
- NCT02994056
- Testing
- SOF/VEL, RBV
- Where
- 12 sites in United States, France
- Volunteers
- 32 people
- Sponsor
- Gilead Sciences
Chronic Hepatitis C, Oxidative Stress
Safety, Metabolism, and Antioxidant Activity of Silymarin and Green Tea Extract in Patients With Chronic Hepatitis C
The purpose of this study is to determine if the safety, metabolism, and antioxidant activity of silymarin and green tea extract are changed when they are given in combination to patients with chronic hepatitis C infection.
- Trial name
- NCT01018615
- Testing
- silymarin, green tea extract (EGCG)
- Where
- United States
- Volunteers
- 28 people
- Sponsor
- University of North Carolina, Chapel Hill
Hepatitis C, HIV
Monitoring Liver Disease Progression in Hepatitis C/HIV Co-infected Patients With No-to-moderate Fibrosis, in Phnom Penh, Cambodia
Data on the progression of liver fibrosis in patients co-infected with HIV taking effective suppressive antiretroviral therapy with no fibrosis or mild-to-moderate fibrosis at baseline are scarce.
- Trial name
- HCV-Monitoring (NCT02628691)
- Testing
- Liver fibrosis progression
- Where
- Cambodia
- Volunteers
- 70 people
- Sponsor
- Institute of Tropical Medicine, Belgium
Hepatitis C
Dose Escalation Study of Interleukin-7 (IL-7) and Bitherapy in HCV Genotype 1 or 4 Patients Resistant to Bitherapy Alone
This study is designed to evaluate the safety of biological active dose of a new experimental drug, IL-7, in combination with standard bi-therapy in patients with Hepatitis C chronic infection identified as non responders to the…
- Trial name
- Eclipse 2 (NCT01025297)
- Testing
- Interleukin-7
- Where
- 8 sites in France, Italy and 1 more
- Volunteers
- 18 people
- Sponsor
- Cytheris SA
HBsAg(+) Donor Kidney Allograft, HBsAg(-) Donor Kidney Allograft
Hepatitis B Antigen Kidney Graft Into Protective Level Hepatitis B Antibody Recipients
To determine the safety of using kidney organ from hepatitis B surface antigen positive donor, the author conducted the single-center, prospective study of the use of these kidneys for recipients who have protective level of…
- Trial name
- NCT02044588
- Testing
- HBsAg positive kidney allograft donor
- Where
- Thailand
- Volunteers
- 100 people
- Sponsor
- Chulalongkorn University
Chronic Hepatitis B
Study to Evaluate the Antiviral Efficacy, Safety and Tolerability of Tenofovir Disoproxil Fumarate Versus Placebo in Pediatric Participants With Chronic Hepatitis B Infection
The primary objective of this study is to evaluate the antiviral efficacy of tenofovir disoproxil fumarate (tenofovir DF; TDF) versus placebo in pediatric population (aged 2 to < 12 years at the time of enrollment) with chronic…
- Trial name
- NCT01651403
- Testing
- Tenofovir DF
- Where
- 21 sites in United States, India and 3 more
- Volunteers
- 90 people
- Sponsor
- Gilead Sciences
Hepatitis B, Hepatitis C
Investigation of Hepatitis B and Hepatitis C in Taiwan
The purpose of this study is to investigate the differences of genotypes of hepatitis B and hepatitis C in Taiwan.
- Trial name
- NCT00946010
- Testing
- blood sampling and abdominal sonography
- Where
- Taiwan
- Volunteers
- 6,228 people, healthy volunteers welcome
- Sponsor
- National Taiwan University Hospital
Hepatitis C Virus
Safety Study of Recombinant Interferon Variant(PEG-IFN-SA) to Treat HCV Disease
The purpose of this study is to determine whether PEG-IFN-SA is safe, tolerant and effective in the treatment of HCV patients.
- Trial name
- PEG-IFN-SA (NCT01605513)
- Testing
- interferon
- Where
- China
- Volunteers
- 80 people
- Sponsor
- The First Hospital of Jilin University
Hepatitis C
Neuropsychiatric Adverse Effects in Patients With Chronic Hepatitis C Treated by Direct Acting Antiviral Drugs
Neuropsychiatric adverse effects of direct acting antiviral drugs, especially Sofosbuvir and Daclatasvir combination therapy (with or without ribavirin) in patients with chronic hepatitis C , genotype four (the predominant…
- Trial name
- NCT03268317
- Volunteers
- 100 people
- Sponsor
- Assiut University
Non-Alcoholic Steatohepatitis(NASH), Hepatitis C
Blood Collection Biorepository for Liver Disease Research
The purpose of establishing a biorepository is to provide high quality specimens (serum, plasma, buffy coat and liver tissue) for future researchers who are studying the effects that fatty liver and viral diseases have on the…
- Conditions
- Non-Alcoholic Steatohepatitis(NASH), Hepatitis C, Hepatitis B, Fibrosis
- Trial name
- NCT03025074
- Where
- United States
- Volunteers
- 1,000 people, healthy volunteers welcome
- Sponsor
- State University of New York at Buffalo
Hepatitis C
Safety, Pharmacokinetics, and Pharmacodynamics of MK-2248 in Participants With Hepatitis C (MK-2248-002)
The objective of this study is to identify a safe dose of MK-2248 in participants with Hepatitis C Virus (HCV) that mediates at least a 3 log10 reduction in viral load (VL) from baseline.
- Trial name
- NCT02161510
- Testing
- MK-2248
- Volunteers
- 13 people
- Sponsor
- Merck Sharp & Dohme LLC
Portal Hypertension
Treatment of Moderate and Severe Cirrhotic Portal Hypertension Due to HBV With Fuzheng Huayu and Entecavir
Portal hypertension is a common pathology in chronic liver disease, particularly in liver cirrhosis. Hepatitis B Virus (HBV) is one of most etiologies of liver cirrhosis in China.
- Trial name
- NCT02945982
- Testing
- Entecavir+Carvedilol, Entecavir+Carvedilol+ Fuzheng Huayu
- Where
- 3 sites in China
- Volunteers
- 184 people
- Sponsor
- ShuGuang Hospital
Hepatitis B, Chronic, Hepatitis C, Chronic
Peginterferon Alfa-2a Plus Ribavirin for Chronic Hepatitis C/Hepatitis B Co-Infection and Chronic Hepatitis C
The investigators' pilot study indicates that hepatitis C virus (HCV)- and hepatitis B virus (HBV)-coinfected patients with predominantly active hepatitis C and those with predominantly active hepatitis B may need different…
- Trial name
- NCT00154869
- Testing
- Peginterferon Alfa-2a plus Ribavirin
- Where
- Taiwan
- Volunteers
- 320 people
- Sponsor
- National Taiwan University Hospital
Chronic Hepatitis C
Pioglitazone in Hepatitis C
The presence of insulin resistance (IR) appears to be a key factor in the development of steatosis and disease progression in patience with Hepatitis C virus (HCV) genotype-1 infections similar to levels in Non-alcoholic fatty…
- Trial name
- NCT00189163
- Testing
- Pioglitazone
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- University of Michigan
Hepatitis C, HIV
Assessing Long-term CTN 0049 Outcomes, HCV Prevalence and Progression Along the HCV Care Continuum Among HIV/HCV Co-infected Substance Users in the U.S.
Primary Objective: This study will evaluate the effectiveness of an HCV Care Facilitation intervention in moving HIV/HCV co-infected substance users forward along the HCV care continuum (compared with a Control group).
- Conditions
- Hepatitis C, HIV, AIDS, Substance Use
- Trial name
- CTN 0064 (NCT02641158)
- Testing
- Control Group, Care Facilitation Group
- Where
- 11 sites in United States
- Volunteers
- 422 people
- Sponsor
- Columbia University
Hepatitis B Virus, Allograft
Risk of Hepatitis B Virus Reactivation in Patients Undergoing Allografting
The purpose of this study is to evaluate the risk of hepatitis B reactivation in patients undergoing allografting.
- Conditions
- Hepatitis B Virus, Allograft, Hematological Malignancies
- Trial name
- NCT00876148
- Where
- Italy
- Sponsor
- Azienda Ospedaliera San Giovanni Battista
Hepatitis B
New Methods to Measure the Immune Response to Hepatitis B Vaccine
Hepatitis B vaccine is a safe and effective vaccine used widely throughout the world. Because of this it is a useful vaccine in which to develop new methods for studying immune responses.
- Trial name
- NCT01821547
- Testing
- Hepatitis B vaccine
- Where
- United Kingdom
- Volunteers
- 21 people, healthy volunteers welcome
- Sponsor
- University of Oxford
Hepatitis C, Depressive Disorder, Major
Prevention of Depression in HIV/HCV Co-infected Substance Abuse Patients
The purpose of this study is to determine whether cognitive behavioral therapy (CBT) is effective in the prevention of depression during interferon and ribavirin treatment for hepatitis C infection.
- Conditions
- Hepatitis C, Depressive Disorder, Major, Depressive Disorder, Depression
- Trial name
- NCT00655226
- Testing
- Hepatitis C educational support groups, Cognitive Behavioral Therapy skills based group sessions
- Where
- United States
- Volunteers
- 26 people
- Sponsor
- Icahn School of Medicine at Mount Sinai
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.